Navigation Links
Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
Date:11/4/2011

SAN FRANCISCO, Nov. 4, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.  The trial is evaluating the use of JX-594 to treat patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC), who failed prior therapy with sorafenib (Nexavar®), the only approved drug for advanced HCC.  In addition, Jennerex earned a milestone payment from its development and commercialization partner, Transgene, based on the randomization of the first patient in the TRAVERSE clinical trial.

"JX-594, with its targeted, multi-mechanistic approach, could offer liver cancer patients a distinct therapeutic alternative, even after they have failed all approved treatment options," stated David H. Kirn, M.D., president and chief medical officer of Jennerex.  "We are building on the positive results of our recent Phase 2 clinical trials evaluating JX-594 in advanced liver cancer both as a single agent and as followed by sorafenib (Nexavar®)."

The TRAVERSE Phase 2b clinical trial is designed to enroll 120 patients with advanced liver cancer who have failed sorafenib therapy. The randomized study will be conducted at approximately 45 sites worldwide including North America, South Korea, Taiwan, Hong Kong, and Europe. The primary objective of the trial is to determine the overall survival benefit for patients receiving JX-594 with best supportive care, compared to best supportive care alone in patients with refractory advanced liver cancer. For more information about the trial, please visit www.clinicaltrials.gov.

Recent Clinical Data f
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p02316662/Global-Chelating-Agents-Market-2014-2018.html About Chelating Agent A ... form covalent bonds with metal ions, thereby forming ... that some metal-ions have on chemical processes, formulations, ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 According to ... continues to reshape the look and feel of markets ... demand for higher-quality ingredients will push for more branded, ... market have experienced strong market growth in the last ... in their food and cosmetics to fit a more ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... BUFFALO, N.Y. -- A novel device, developed by ... simply and conveniently traps, detects and manipulates the ... obstacles that have prevented progress toward spintronics and ... Physical Review Letters, the research paper brings closer ...
... 28 PPD, Inc. (Nasdaq:,PPDI) will release its third ... market closes. The earnings release will be available,on the ... PR Newswire. On Wednesday, October 24, at 9 ... audio webcast to discuss financial results and the,overall business ...
... LAVAL, QC, Sept. 28 /PRNewswire-FirstCall/ - Neptune Technologies ... report its,financial results for the fiscal year ended ... improved its productivity and operational,profitability while continuing its ... Asian markets, resulting in,sustainable sales growth. Financial ...
Cached Biology Technology:Quantum device traps, detects and manipulates the spin of single electrons 2PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call 2Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results 2Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results 3
(Date:8/27/2014)... LAKE CITY, Aug. 27, 2014 University of Utah ... his native Turkey, has won that nation,s highest science ... of Science. , Sekercioglu is among five researchers picked ... and Technical Research Council of Turkey. Three researchers won ... won the Special Award, which is equivalent to the ...
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
(Date:8/27/2014)... 27, 2014 /PRNewswire-iReach/ -- The IEEE Engineering in Medicine ... Annual International Conference (EMBC,14), this year being held ... Chicago, Illinois , from Tuesday, August 26 ... students, and industry professionals in science, medicine, and engineering ... http://photos.prnewswire.com/prnh/20140827/140333 This year,s conference theme ...
Breaking Biology News(10 mins):University of Utah biologist wins Turkey's top science prize 2Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3
... the year,s end-of-life refrigerators, TVs, mobile phones, computers, monitors, ... cord worldwide could fill a line of 40-ton trucks ... Equator. That forecast, based on data compiled by ... of UN organizations, industry, governments, non-government and science organizations ...
... many of the harmful physiological effects of short-term overeating and ... The Journal of Physiology , which is well timed with ... even a few days of energy surplus where you ... impacts. This new study shows that a daily bout of ...
... organisms evolved from earlier life forms. At the ... help complete chemical processessuch as converting food into energyin ... University of Iowa researcher and his colleagues describe the ... as it occurred from bacteria to humans. Their paper, ...
Cached Biology News:World e-waste map reveals national volumes, international flows 2World e-waste map reveals national volumes, international flows 3World e-waste map reveals national volumes, international flows 4World e-waste map reveals national volumes, international flows 5Exercise counters the physiological effects of Christmas excess 2UI researcher studies evolution on the molecular level 2
... Validation Service enables early selection of ... by providing quantitative data for sensitivity, ... each antibody. Furthermore quantitative antibody fingerprints ... activity of your antibodies., The full-service ...
... fluorescent microscopy-based imaging system that accurately counts ... calculates cell viability, in a single test. ... variability associated with the subjective interpretation of ... EasyCount ViaSure Kit, up to six tests ...
... new generation of microarrays to detect alternative ... to rapidly elucidate alternatively spliced events in ... drug discovery. The service combines ExonHits proprietary ... customized analysis with Agilents robust microarray platform. ...
... The new Adept CE 4100 ... provides superb flow precision, with software drive ... rates from 0.001-10mL/min are selectable in 0.001mL ... inserts, are inert and bio-compatible., Pumps may ...
Biology Products: